Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMP001 in Relapsing-remitting Multiple Sclerosis
NCT02686788Phase 2Completed
- Sponsor
- Dr. Frank Behrens
- Start
- Aug 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tarenflurbil in relapsing-remitting multiple sclerosis (RRMS), sponsored by Dr. Frank Behrens. Primary endpoint: Average total number of contrast enhancing lesions at 24 weeks. Started Aug 2015; status: completed.
02
Drugs
tarenflurbil
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02686788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02686788.